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Approximately 7 million people are affected by acute myocardial infarction (MI) each
year, and despite significant therapeutic and diagnostic advancements, MI remains a
leading cause of mortality worldwide. Preclinical animal models have significantly
advanced our understanding of MI and have enabled the development of therapeutic
strategies to combat this debilitating disease. Notably, some drugs currently used to
treat MI and heart failure (HF) in patients had initially been studied in preclinical ani-
mal models. Despite this, preclinical models are limited in their ability to fully repro-
duce the complexity of MI in humans. The preclinical model must be carefully
selected to maximise the translational potential of experimental findings. This review
describes current experimental models of MI and considers how they have been used
to understand drug mechanisms of action and support translational medicine
development.
K E YWORD S
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1 | INTRODUCTION
Cardiovascular diseases (CVDs) remain the leading cause of death
worldwide accounting for 31% of all deaths, approximating to 17.9
million people each year (Virani et al., 2020). Acute myocardial infarc-
tion (AMI) leading to ST-elevation myocardial infarction (MI) (STEMI)
is clinically defined as permanent and irreversible damage to the heart
following acute myocardial ischaemia (Thygesen et al., 2018). STEMI
is the result of abrupt complete and persistent occlusion of one or
more coronary arteries that supply the myocardium, resulting in pro-
longed myocardial ischaemia with irreversible tissue damage
(Thygesen et al., 2018), in the presence or absence of
Abbreviations: APD, action potential duration; ANP, atrial natriuretic peptide; ARB, angiotensin receptor blocker; ARNIs, angiotensin receptor neprilysin inhibitors; BZ, border zone; CO, cardiac
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atherothrombotic plaque rupture (Sandoval & Jaffe, 2019). Although
overall mortality has been considerably reduced, due to advances in
pharmacological, procedural and lifestyle interventions, survivors of
MI are at higher risk of recurrent MI as well as other CVDs such as
serious bleeding events, arrhythmias and congestive heart failure
(HF) (Fox et al., 2006; Johansson et al., 2017). The associated morbid-
ity and requirement for lifelong therapy pose substantial societal and
economic costs. Current recommended therapeutic interventions
(Ibanez et al., 2018) mitigate these risks to some extent, but there is
still the need for the discovery of new therapeutic agents to reduce
chronic disease (e.g., HF) developing subsequent to MI. Preclinical
studies in animal models of MI are vital in this drug discovery process.
Angiotensin-converting enzyme (ACE) inhibitors, for example, were
first described to be of benefit in a rat model of coronary artery
ligation-induced MI (Pfeffer, Pfeffer, & Braunwald, 1985; Pfeffer,
Pfeffer, Steinberg, & Finn, 1985) and went on to transform the out-
look for patients with HF. However, outcomes in experimental models
do not always translate well to the clinic, notably interventions
designed to protect the heart from acute ischaemia (Kloner
et al., 2017). Innovations in non-invasive imaging have opened a new
window on human myocardial disease, including MI (Curley
et al., 2018), but we are still predominantly dependent on preclinical
models for deeper mechanistic understanding and for testing the util-
ity of new therapeutic agents.
In this review, we discuss the most common preclinical models of
MI currently employed in cardiovascular research. Furthermore, we
discuss how these models can be used to identify novel therapeutic
targets with translational potential to limit adverse cardiac remodelling
after MI and the challenges of translation including the influence of
sex, co-morbidities and co-medication.
1.1 | Pathophysiology of post-MI remodelling
Myocardial ischaemia starves cardiomyocytes of vital oxygen lead-
ing to acute cardiomyocyte death and necrosis within the infarct
zone (IZ). The surviving cardiomyocytes immediately surrounding
the IZ create a transcriptomically and functionally distinct border
zone (BZ), where tissue can be salvaged or die, leading to expan-
sion of the initial infarct. Damage-associated molecular patterns
(DAMPs) and chemokines released from resident myocardial cells
(Gray et al., 2018) attract neutrophils and macrophages into the IZ
and BZ to phagocytose dead cardiomyocytes and clear the myocar-
dium of matrix debris in preparation for subsequent cardiac repair
(Horckmans et al., 2017; Wan et al., 2013). Free radicals and a
host of cytokines (Frangogiannis, 2012) are released and along with
MMPs that promote extracellular matrix (ECM) remodelling and
facilitate a shift towards repair. Reparative macrophages now domi-
nate, and reparative neutrophils (Ma et al., 2016), recruited T cells
and eosinophils (Toor et al., 2020) also play a crucial role in repair
of the myocardium. Angiogenesis and lymphangiogenesis in the BZ
permit cardiomyocyte salvage and promotion of vessel maturation
and can prevent infarct expansion beyond the IZ (see Klaourakis
et al., 2021). In the absence of any significant level of car-
diomyocyte proliferation to replace injured tissue in the adult heart,
rapid replacement by a collagen scar is essential to maintain the
integrity of the myocardium. Cardiac fibroblasts releasing TGF-β
have a key role in this process, differentiating into a proliferative
myofibroblast phenotype that deposits collagen to promote robust
scar formation (Frangogiannis, 2012). With a sudden massive loss
of cardiomyocytes within the IZ, electrophysiological remodelling
and contractile dysfunction follows within cardiomyocytes of the
BZ, as well as the remote zone (RZ) of non-infarcted myocardium
(Hegyi et al., 2018), often resulting in ventricular arrhythmias
(Mendonca Costa et al., 2018) that can lead to sudden death
after MI.
Molecular and cellular changes in the heart after MI lead to ven-
tricular contractile dysfunction and changes to left ventricular
(LV) architecture including wall stress, dilation, myocardial stiffness,
infarct expansion and thinning of the myocardium (collectively
referred to as adverse cardiac remodelling). Infarct size, dilation and
impaired contractility (e.g., reduced ejection fraction [EF]) are major
indicators of consequent adverse cardiovascular outcomes including
HF and mortality (Konstam et al., 2011). With reduced LV contraction
and increased pressures, neurohumoral activation (renin–angiotensin–
aldosterone system [RAAS]) becomes augmented in a bid to maintain
cardiac output (CO). Together with neurohumoral activation and an
imbalance of perfusion/demand, cardiomyocyte Ca2+-handling pro-
tein function becomes impaired (Elliott et al., 2011; Miller
et al., 2005), promoting a demise in contractile function and a transi-
tion from prohypertrophy to proapoptosis, particularly within the BZ
region (Gilson et al., 2007).
1.2 | Current treatment and therapies:
Opportunities for translational innovation
The first line of treatment essential to patient survival following MI is
timely and effective reperfusion of the infarcted myocardium by pri-
mary percutaneous coronary intervention (PPCI) to salvage as much
viable myocardium as possible and preserve LV systolic function.
Indeed, PPCI when performed with adjunctive therapies
(e.g., abciximab to reduce thrombus formation) has greatly reduced
mortality following MI (Alyamani et al., 2020; Cahill &
Kharbanda, 2017; Morales-Ponce et al., 2019). Current pharmacologi-
cal therapies (Bauersachs, 2021) for the treatment of HF include
inhibitors of the mineralocorticoid receptor (eplerenone [Serenelli
et al., 2020]), the sympathetic nervous system (van Bilsen
et al., 2017), the sodium–glucose cotransporter 2 (SGLT2;
dapagliflozin [McMurray et al., 2020]), the RAAS (ACE inhibitors;
enalapril [McMurray et al., 2014]; angiotensin receptor blockers
[ARB]; valsartan), the natriuretic system (neprilysin inhibitor sacubitril)
or a combination of therapies such as sacubitril/valsartan (angiotensin
receptor/neprilysin inhibitors [ARNIs]) that have been shown to be
more effective at treating HF over a range of ejection fractions (Jhund
& McMurray, 2016).
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Although these therapies, to varying degrees, are effective at
limiting adverse cardiovascular outcomes by unloading the heart fol-
lowing MI and reducing the likelihood of adverse remodelling, they
do not prevent loss of cardiomyocytes due to ischaemia that eventu-
ally results in HF. Preclinical studies have shown that promotion of
angiogenesis by VEGF (Wu et al., 2021), modulation of macrophage
phenotype to promote repair (see Huang & Frangogiannis, 2018),
inhibition of the NLRP3 inflammasome (Reitz et al., 2019; van Hout
et al., 2017) or limiting fibrosis (Vainio et al., 2019) can all prevent
infarct expansion. Moreover, with the advances in transcriptome ana-
lyses, new targets are being identified (Li et al., 2019). Nevertheless,
none of these has been successfully translated into the clinic
and, currently, there are no treatments specifically targeting infarct
repair.
The underlying cellular and molecular processes involved in post-
MI cardiac remodelling are not fully understood. Therefore, preclinical
cardiovascular models are crucial in the discovery and development of
novel and efficacious therapeutic strategies to limit the effects
of morbidity after MI. Different preclinical models can be used to
answer different questions. For example, some models further our
mechanistic insight with high translational potential to the clinical set-
ting, whereas others may have low translational potential and provide
only basic mechanistic understanding of novel targets. However, the
latter should not be undervalued as outcomes from these models
often shape further investigations.
2 | IN VIVO MODELS OF MI
With advances in specialist microsurgical and imaging/diagnostic
equipment, rodents are the animal of choice for initial preclinical
investigation. Translational relevance of various targets identified
from ex vivo/in vitro and human studies can be examined with
high turnover using rodents. The use of mice is often desirable
due to the knowledge of its genome, abundant variety of geneti-
cally modified strains, its short gestation and its relatively low cost
for breeding and maintenance. Nevertheless, studies aimed at
developing new imaging modalities and tracers (Curley et al., 2018;
MacAskill et al., 2021) generally use rat due to the image
acquisition obstacles faced when using mice such as small heart
size (5- to 8-mm adult heart length) and high heart rates
(400–660 bpm). After initial investigations using rodents, rabbits
can be a useful model to accompany large animal studies. Indeed,
they have cardiac electrophysiology more comparable to that in
humans, than that in rodents (Kumar et al., 2016) and so can be
used to model electrophysiological changes following MI. The larger
rabbit heart size makes it technically easier to perform MI surgical
procedures compared with rodents, yet the equipment and facilities
required are not as extensive as for larger models (discussed in
Section 2.3). Thus, the following section will mainly focus on initial
preclinical rodent studies.
2.1 | Irreversible ischaemia models
2.1.1 | Left anterior descending coronary artery
ligation
A commonly used method to assess MI and longer term post-MI car-
diac remodelling is surgical permanent occlusion of the left anterior
descending coronary artery (LAD), modelling acute STEMI in patients
(Figure 1). Following anaesthetisation and intubation, a left-sided
F IGURE 1 Left anterior descending coronary artery (LAD) ligation in mice. Following anaesthesia and intubation of the animal, a thoracotomy
is performed between the third and fourth ribs. The tissue and muscle (m. pectoralis minor and m. pectoralis major) are carefully bluntly dissected
before the thorax is entered. Surgical stays are used to retract the tissue to allow visualisation of the heart (a). Once the heart is located, the
pericardium is gently opened ensuring that nothing causes damage to the lungs. The LAD, situated between the pulmonary artery and left atrium,
is identified and ligated 2–3 mm below the atrium using a single 9-0 suture. The permanent ligation prevents distal perfusion and is confirmed by
myocardial blanching (b) and/or ECG. The thoracic incision is closed using 6-0 prolene, and the lungs are reinflated by briefly (4 s) pinching the
ventilator outflow and placing it in water to keep positive pressure in the thoracic cavity. The muscles are gently pulled back into position, the
skin is closed with simple interrupted sutures, the ventilator outflow tube is reconnected and the animal is removed from the ventilator once
spontaneous breathing matches the rate of the ventilator. Images courtesy of Ashley Bradley
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thoracotomy is performed, and the LAD is ligated. The permanent
ligation (PL) prevents distal perfusion causing irreversible hypoxia in a
large proportion of the LV resulting in cardiomyocyte cell death, apo-
ptosis and infarct scar formation. The thoracic incision is closed
followed by reinflation of the lungs, closure of the skin and the animal
allowed to recover.
PL is widely used to model the 30% of patients in which timely
reperfusion did not occur or reperfusion failed. Thus, this model
allows investigation of the cellular and molecular mechanisms follow-
ing tissue injury and wound healing. With increased haemodynamic
load following sudden cardiomyocyte necrosis, contractile dysfunction
and thinning of the LV posterior wall can be observed as early as
1 day after MI (Fattah et al., 2016; Sicklinger et al., 2020). Activation
of multiple intracellular signalling cascades (Prabhu &
Frangogiannis, 2016) and adverse cardiac remodelling leads to the ini-
tiation of asymmetrical LV remodelling that includes the key hallmarks
of human MI including thinning of the LV free wall, thickening of the
septal non-ischaemic LV wall (Lindsey, Kassiri, et al., 2018), increased
wall stress leading to progressive dilation, expansion of the scar and
deterioration of cardiac function.
This technique presents considerable challenges in mice, requiring
a high level of skill with microsurgical techniques. Complications can
include tissue damage and high perioperative mortality rates as a
consequence of intraoperative bleeding, the lungs experiencing dam-
age or collapsing, ligation errors or inadequate ventilation (Gao
et al., 2010). With the small size of the mouse heart, specialist micro-
surgical equipment is required, such as a dissection microscope, and a
highly skilled surgeon to carry out the technically demanding and
precise ligation of the LAD; the success of which can be operator-
dependent. Resulting infarct size (as %LV area) can be highly variable
(10–45%) for the inexperienced surgeon but with experience can be
narrowed down to be considerably more consistent, for example, 35
± 5%. The extent of LV remodelling is correlated with infarct size.
Indeed, a major advantage of using the PL method is that the extensive
infarct induced provides more distinct differences in cardiac function
between sham and MI animals. Mice are more resistant to developing
HF than humans and tend to maintain sufficient cardiac function fol-
lowing large infarcts, thus allowing assessment of severe injury for
several weeks after MI (Sam et al., 2000). This is particularly advanta-
geous when investigating long-term post-MI remodelling and testing
the efficacy of novel therapies (Bayat et al., 2002; Sam et al., 2000).
However, permanent occlusion and resultant large infarcts as pro-
duced in this model are less frequently observed in humans.
Variation of infarct size is dependent upon LAD anatomy, ligature
location (Kumar et al., 2005), mouse strain, age and sex (Bayat
et al., 2002; Gao et al., 2000; Gao et al., 2010; Sam et al., 2000), and
these factors should be considered when designing investigations. In
the hands of a highly experienced surgeon, post-operative mortality is
low. However, in mice, myocardial rupture can occur typically
3–5 days following MI (Gao et al., 2000; Salimova et al., 2019). Rup-
ture is dependent on several factors, including ECM remodelling,
inflammation and the genetic strain (Frangogiannis, 2012), although is
rarely observed in rats.
Variations of this model include a rapid less invasive method that
does not require ventilation, resulting in lower mortality and higher
survival rates (Gao et al., 2010; Sun et al., 2018). The first method is
performed by a small skin incision followed by dissection and retrac-
tion of the muscles exposing the fourth intercostal space, allowing a
small hole to be made, which allows the heart to ‘pop out’. The LAD
is ligated, the heart is placed back into the chest, air is manually
removed from the thoracic cavity, and the muscles and skin were
closed (Gao et al., 2010). Limitations of this model include technical
challenges such as limiting global hypoxia if the heart is kept outside
the chest for >30 s and death due to pneumothorax (Gao et al., 2010).
A second minimally invasive yet technically challenging variation is to
use ultrasound-guided ligation of the LAD via two small skin incisions
on the left and right chest to expose the third intercostal space. A
straight needle with attached suture is then passed from left to right
and right to left through the heart surface encompassing the LAD and
the suture tied (Sun et al., 2018). Using either of these models results
in a comparable degree of cardiac dysfunction and infarct size com-
pared with the open-chest method but with a reduction in inflamma-
tion and mortality (Gao et al., 2010; Sun et al., 2018). Similar
minimally invasive approaches have been undertaken in rabbits (Fujita
et al., 2004).
2.1.2 | Ablation methods
Other methods of inducing permanent myocardial injury are ablation
methods via cryoinjury or electrical damage. Overall, these models
generate reproducible and uniformly sized—and uniformly shaped—
infarcts with precise localisation, compared with LAD ligation and
therefore are commonly used in therapeutic intervention studies in
rodents (van Amerongen et al., 2008). The cryoinjury model involves a
thoracotomy, pericardiectomy and cryoinfarction performed using
a cryoprobe (3 mm for mouse and 9 mm for rat) applied to the ante-
rior LV free wall for 10 s, using positioning of the left atrium and pul-
monary artery for guidance (van den Bos et al., 2005). This method
initiates a decline in LV function comparable to that obtained with
LAD ligation, albeit with reduced cardiac remodelling, smaller and
thicker scar formation, and improved survival rates (Wang
et al., 2019). Interestingly, scar formation is not fully resolved after
cryoinjury (Lam & Sadek, 2018), and differences to the MI model may
be instructive in understanding the pathophysiology of the scar
region.
A variation of the above model is the freeze–thaw injury model
whereby a pre-cooled (190C) rod is placed on the heart several
times to induce injury, resulting in progressive LV remodelling and
dilation (Ciulla et al., 2004; Huwer et al., 1998). With cryoinfarction,
cardiomyocyte necrosis and cell membrane disruption ensue in con-
trast to hypoxia-induced apoptosis. Thus, the molecular signalling
mechanisms activated in cardiomyocytes may vary between models
and important differences in infarct morphology are also observed.
Following cryoinjury, the IZ starts from the epicardial surface rather
than propagating outward from the inner endocardial layers. This
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results in precise borders between the IZ and RZ, rather than having a
BZ with damaged yet viable and variably oxygenated cardiomyocytes,
as in the LAD method (Ciulla et al., 2004; van den Bos et al., 2005).
Recently, a minimally invasive method of electrical ablation describes
ultrasound-guided, coronary artery coagulation, using precise
micromanipulator-controlled high-frequency electricity (Sicklinger
et al., 2020). Requiring expertise in imaging, this closed-chest
approach (no thoracotomy or intubation required) allows immediate
assessment of cardiac function after injury and reports similar LV dys-
function and infarct size as LAD ligation, but with lower welfare
concerns and higher survival rates (Sicklinger et al., 2020).
2.2 | Reperfusion models
2.2.1 | LAD followed by reperfusion
Timely reperfusion following ischaemia (I/R) salvages ischaemic myo-
cardium, resulting in reduced infarct size, increased LV function and
increased survival (Burke & Virmani, 2007; Hashmi & Al-Salam, 2015).
Reperfusion therapy is performed by PPCI, balloon angioplasty or
thrombolysis in 70% of patients after MI (Cohen et al., 2010;
Lindsey, Bolli, et al., 2018). Successful revascularisation of the myocar-
dial tissue is the most effective therapy for reducing infarct size in
patients, producing the best clinical outcomes, including reduced mor-
tality (Lonborg et al., 2013; Stone et al., 2016). Experimental cardiac
I/R has been an important MI model for many years because it most
resembles the clinical scenario of PPCI (Heusch & Gersh, 2017; Johns
& Byron, 1954; Saÿen et al., 1951). Technical approaches for I/R vary
between research groups, and differing species are utilised, as distinct
and specific methodologies are required for the particular research
question posited (Abarbanell et al., 2010; Kumar et al., 2016). Signifi-
cant and continuous efforts have been made to refine and standardise
I/R surgical techniques and protocols (Gao et al., 2010; Lindsey, Bolli,
et al., 2018; Xu et al., 2014).
In vivo I/R experiments begin with a left-sided thoracotomy to
the anesthetised animal. At this point, typically, the chest cavity is
opened, exposing the heart (Virag & Lust, 2011; Xu et al., 2014), or a
closed-chest approach is taken for the ligation (Kim et al., 2012). The
closed-chest approach is particularly beneficial when the inflamma-
tory response arising from the surgical trauma may potentially con-
found results (Kim et al., 2012). A suture is tied and tightened around
TABLE 1 Comparison of permanent ligation and ischaemia/reperfusion models of MI
Permanent ligation (PL) Ischaemia/reperfusion
Characterisation • Sustained ischaemia via LAD occlusion
• Irreversible hypoxia resulting in cell death
and infarct scar formation
• Temporary ischaemia via LAD occlusion
followed by restoration of blood flow
• Hypoxia can be reversible or least
partially reversible
Cellular response • Hypoxia causes transition to anaerobic
glycolysis resulting in # ATP, # pH and "
cytosolic Ca2+ and Na+ leading to cell
swelling, rupture, and death and
activation of robust inflammatory
response
• Initial response same as PL, then
reperfusion reintroduces oxygen, and the
return to aerobic metabolisms results in
normalised pH and ionic homeostasis,
attenuating cell swelling and death
• Reperfusion can exacerbate injury by "
inflammatory response, " ROS and
"cytosolic Ca2+
Pathology • Extensive infarct, contractile dysfunction,
# ejection fraction, " wall stress, wall
thinning and thickening of
interventricular septum
• Generally smaller infarcts and less
extensive remodelling
• Preserved or recovered ventricular
function and different inflammatory
responses even if infarct is the same size
as a heart after PL
Translation Advantages
• Larger infarct allows more definitive
comparison between sham and infarcted
animals
• Consistent infarct size valuable for
experimental reproducibility
Disadvantages
• Not representative of most common
clinical situation (only 15–30% of
people in clinical scenario are either too
late for reperfusion therapy or it is not
successful)
Advantages
• Representative of clinical situation as
reperfusion therapy is the frontline
treatment for ischaemia
• Extent of cell death and infarct size
proportionate to duration of ischaemia
Disadvantages
• Can confound results as it is difficult to
distinguish the response to the initial
injury vs. reperfusion injury
• Procedure is technically demanding, and
the size of the infarct can be highly
variable, challenging experimental
reproducibility
Abbreviations: LAD, left anterior descending coronary artery; PL, permanent ligation.
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both the LAD and a small piece of tubing, occluding blood flow to the
LV. Shortly following the ligation, the anterior wall of the LV becomes
pale in colour, confirming occlusion of the artery. Ischaemia is
maintained for the chosen length of time (which is generally less than
60 min) before the suture is cut and loosened or the tubing is
removed, initiating reperfusion. Although the cellular response to LAD
occlusion is similar (Table 1), the pathological outcomes differ
between PL and I/R approaches with the latter resulting in a substan-
tially smaller infarct (de Villiers & Riley, 2020; Hashmi & Al-
Salam, 2015). Infarct size in I/R models can be highly variable
depending on the duration of the occlusion and reperfusion. Unsur-
prisingly, longer ischaemic periods result in cell death beginning in the
endocardium and progressing outward towards the epicardium
(Reimer et al., 1977), resulting in more severe infarcts (de Villiers &
Riley, 2020). Less than 15 min of ischaemia results in reversible injury,
whereas 2 h or more can cause as much damage as PL (Michael
et al., 1999). Furthermore, genetic strain, sex, age and occlusion loca-
tion on the LAD significantly alter the region affected (Garcia-Dorado
et al., 1987; Michael et al., 1999; Reimer et al., 1977). Interestingly,
even when PL and I/R models have equivalent infarct size, the I/R
hearts have preserved or restored ventricular function and different
inflammatory responses (Hashmi & Al-Salam, 2015; Michael
et al., 1999). For a useful I/R study, the LAD must be ligated for suffi-
cient time to induce an ischaemic response without sustaining the
occlusion to the point of irreversible injury, which is typically 30 min
to 1 h in duration, but ranges from 10 min to 2 h depending on the
study. Successful reperfusion will result in the tissue returning to a
pink–red colour. Although initially most I/R studies utilised large ani-
mal models (Garcia-Dorado et al., 1987; Saÿen et al., 1951), mice have
become the most commonly selected model species for these investi-
gations by virtue of the relative ease of their genetic manipulation (de
Villiers & Riley, 2020; Lindsey, Bolli, et al., 2018; Michael et al., 1995;
Xu et al., 2014).
The pathophysiological response to ischaemia begins in the
region of myocardium supplied by the occluded LAD. The hypoxia
causes a transition to anaerobic glycolysis, causing a reduction in ATP
and a resulting cascade of drastic intracellular changes, including
reduced intracellular pH and increased cytosolic Ca2+ and Na+ accu-
mulation, which leads to cell swelling and rupture (Burke &
Virmani, 2007). From this point, PL leads to an inflammatory response,
large-scale cell death and infarction. Subsequent reperfusion, how-
ever, reintroduces oxygen allowing for a return to aerobic metabolism.
This normalises the intracellular pH and restores ionic homeostasis,
which attenuates cell swelling, limiting cell death and thus infarct size
(Burke & Virmani, 2007). Paradoxically, although reperfusion rescues
viable myocardium from cell death, reperfusion itself can cause injury,
known as I/R injury, reducing cardiac function and increasing
arrhythmogenesis (Hashmi & Al-Salam, 2015). Re-oxygenation further
exacerbates pathological cytosolic Ca2+ overload by enabling Ca2+
reuptake into the sarcoplasmic reticulum (SR) while enhancing Ca2+
release from the SR (Kalogeris et al., 2012; Valen, 2003). Furthermore,
to re-establish pH, the Na+/H+ exchanger is activated to extrude H+,
resulting in subsequent Na+ influx and activation of the Na+/Ca2+
exchanger to extrude Na+, causing an influx of Ca2+. Re-oxygenation
following ischaemia also induces generation of ROS (causing cellular
dysfunction) and opens the mitochondrial permeability transition pore
(impairing ATP production), both of which induce cell dysfunction or
death (Kalogeris et al., 2012; Valen, 2003). Finally, reperfusion also
accelerates and exacerbates the inflammatory response (Lindsey, Bolli,
et al., 2018). As will be discussed below, experimental models of I/R
are essential for the advancement of both mechanistic and transla-
tional studies involving interventions for acute MI.
2.2.2 | I/R with ischaemic preconditioning
Ischaemic preconditioning is a phenomenon in which brief episodes of
ischaemia cause the myocardium to adapt, increasing its resistance to
subsequent prolonged periods of ischaemia, reducing the size of the
infarct (Hausenloy et al., 2016). Specifically, it was initially observed
that when 40 min of sustained ischaemia was preceded by four 5 min
periods of ischaemia separated by 5 min of reperfusion, the infarct
size was limited by 25% compared with 40 min of sustained occlusion
alone (Murry et al., 1986). Since this seminal study, ischaemic
preconditioning has been confirmed and replicated by many research
groups and in many models (Hausenloy et al., 2016; Przyklenk, 2013).
Much effort has been made to use ischaemic preconditioning and elu-
cidate its cellular mechanisms, with an overall goal of translating this
protective strategy into the clinical setting (Hausenloy et al., 2016).
Preconditioning has two distinct phases of cardioprotection: the
initial phase ≤2 h prior to the sustained occlusion and the second win-
dow of protection, occurring 24–72 h after preconditioning (Pagliaro
et al., 2001). The initial protective phase of preconditioning is due to
activation of complex signalling transduction pathways (that are not
present after PL alone) and thus has been the focus of many investiga-
tions (Heusch, 2015). Specifically, during the reperfusion that follows
the brief preconditioning ischaemic phase, GPCRs are activated, caus-
ing activation of kinase cascades (Heusch & Gersh, 2017;
Przyklenk, 2013). Three signal transduction pathways have been iden-
tified: the reperfusion injury salvage kinase (RISK) pathway, the sur-
vival activating factor enhancement (SAFE) pathway and the NO/PKG
pathway (Heusch, 2015; Przyklenk, 2013). Despite divergent mecha-
nisms, they converge by affecting the mitochondria, inhibiting mito-
chondrial permeability transition pores, resulting in myocardial
protection (Heusch, 2015; Przyklenk, 2013). The second window of
protection, however, acts via a different mechanism, most likely to
involve alteration of gene expression or protein synthesis (Hausenloy
& Yellon, 2010). During the preconditioning ischaemic episode, signal-
ling pathways are initiated which activate transcription factors
resulting in the synthesis of cardioprotective proteins that would not
have been present under normal physiological conditions. Conse-
quently, infarct size is reduced, compared with that after PL, when
prolonged occlusion is preceded by ischaemic episodes, approximately
24 h earlier (Hausenloy & Yellon, 2010).
Ischaemic preconditioning in mice demonstrates benefit including
reduced infarct size, improved contractile function and reduced
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arrhythmogenesis (Valen, 2003). Understanding the molecular mecha-
nisms that result in cardioprotection could lead to the development of
pharmacological interventions that harness and activate these
protective pathways. The nature of ischaemic preconditioning makes
it impossible to utilise in patients. However, it may still have
translational value. Its discovery facilitated the evolution from
preconditioning to both post-conditioning (ischaemic episodes follow-
ing prolonged occlusion) and remote conditioning (I/R in other
organs). Both post-conditioning and remote conditioning have cardi-
oprotective effects experimentally, and there are some reports of
improved clinical outcomes. However, their translational effectiveness
remains to be established (Boukhris et al., 2015; Bromage et al., 2017;
Heusch, 2015; Heusch & Rassaf, 2016).
2.3 | Large animal models of MI
In large animals used to model MI (most commonly pig, mini-pig, sheep
and dogs) heart size, heart rate, vascular anatomy and BP are more
akin to humans, and this makes them the models of choice for transla-
tional medicine (Figure 2) (Heusch et al., 2011; Silva & Emter, 2020).
The larger heart size permits extensive monitoring to gather mecha-
nistic data on regional contractility, perfusion and electrical signalling
by surgical instrumentation or even microdialysis for sample collection
(Heusch et al., 2011). Although not necessarily expensive to purchase,
large animal work requires the availability of specialised facilities for
housing and monitoring, as well as clinical standard surgery and imag-
ing that are expensive to establish and maintain. Drug treatment also
constitutes a significant cost in large animals, particularly for long-term
studies. Nevertheless, when compared with the cost of a failed clinical
trial, a well-designed experimental study in an appropriate large animal
model (Zwetsloot et al., 2017) can represent very good value for
money as part of the translational process.
As in rodents, MI can be induced in open-chest surgery with both
permanent ischaemia and I/R induced by ligation of the coronary
artery. However, the most common model is closed chest where
ischaemia is induced temporarily by inflation of a balloon advanced
into the coronary artery, usually for 30–60 min followed by deflation
and removal of the balloon catheter, allowing reperfusion and mimick-
ing the clinical PPCI procedure (Heusch et al., 2011). As in the clinic,
antiarrhythmic and antithrombotic agents are usually administered
during this procedure. Ventricular fibrillation is more common in pigs
and other large animals after MI than in rodents, and the use of antiar-
rhythmic therapy and/or cardioversion is recommended to reduce
perioperative mortality. Closed-chest ischaemia can also be induced
by creation of a microembolism in the coronary artery, taking the
model even closer to the human condition (Bikou et al., 2019), particu-
larly when combined with hypercholesterolaemia (Andreadou
et al., 2020). In older humans, myocardial ischaemia is frequently the
result of gradual narrowing of coronary arteries, rather than all or
nothing sudden occlusion. In models using larger animals, this can be
reproduced by placement of hydraulic occluders around the
F IGURE 2 Animal models of cardiac injury, regeneration, repair and remodelling
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coronaries or by a fixed cuff that increases occlusion as the animal
grows (Heusch et al., 2011). The extent of collateral vessel develop-
ment varies between species. The dog, with its extensive collateral cir-
culation, replicates more accurately the situation in humans with long-
term multi-vessel disease, although this does result in smaller and
more variable infarcts that are not always ideal for experimental
investigation.
The pace of infarct development is slower in humans than in
rodents, and infarcts tend to be sub-endocardial. These features are
reproduced more accurately in large animals, making them better
models for interventions that seek to reduce infarct injury. Large ani-
mals can be kept for many months, even instrumented, to track
remodelling of the heart and the development of HF (Silva &
Emter, 2020). However, pigs may not reproduce all aspects of
remodelling in human hearts. For example, a recent study has shown
that pig cardiomyocytes grow primarily by multi-nucleation and longi-
tudinal hypertrophy, distinct from mice and humans (Velayutham
et al., 2020). More studies like these are needed to understand the
true translational value of large animal models. Mechanistic studies
are somewhat limited by the availability of suitable tools for interroga-
tion. For example, antibodies are less available for large animals than
for rodents. However, genetic manipulation is possible, and with appli-
cation of CRISPR technology (Yang & Wu, 2018), we can expect
increased availability of large animal models with targeted mutations
in pathways of interest, to understand myocardial infarct injury, repair
and remodelling.
2.4 | Neonatal MI and cardiac regeneration
Amphibia and fish retain the capacity to regenerate their myocardium
after injury without scar formation via cardiomyocyte proliferation
throughout life, and these species are frequently used to study mech-
anisms of regeneration after injury (Beffagna, 2019). In mammals, this
regenerative capacity is limited to the early postnatal period when
cardiomyocyte proliferation is the primary means of cardiac growth
(Cardoso et al., 2020; Castellan, Thomson, et al., 2020). It is lost when
cardiomyocytes become binucleated and undergo cell cycle arrest,
during the first postnatal week in mice. Mammalian scar-free cardiac
regeneration was first described in neonatal mice after ventricular re-
section but has since been demonstrated after MI in mice (see
Cardoso et al., 2020), as well as in large mammals, for example, in
2-day-old pigs (Ye et al., 2018). Several reports in human neonatal
heart, including a case report of a newborn infant with a large MI that
healed by regeneration with full functional recovery (Haubner
et al., 2016), support the translational relevance of these models.
Induction of MI in Postnatal Day 1 mice is technically highly chal-
lenging. As they cannot be adequately ventilated due to their small
size, pups are cooled on ice to stop the heart during surgery and then
slowly rewarmed during recovery. Ischaemia is induced by PL of the
LAD under a surgical microscope using fine tools and sutures (see
video in Blom et al., 2016, for full description). Analgesia (bupivacaine
0.25%) can be applied topically to the skin wound on completion.
Surgery on such young animals is additionally complicated by the need
to reintroduce them to their mothers until weaning. Rolling them in
bedding from the home cage prior to re-introduction is essential to
prevent maternal cannibalisation. Loss of function following injury and
regain of structure and function during regeneration over the follow-
ing 3–4 weeks can be successfully tracked in the lightly anaesthetised
neonatal mouse using ECG-gated high-resolution ultrasound
(Castellan, Thomson, et al., 2020) or MRI (Gunadasa-Rohling
et al., 2018).
Establishment of these models has led to extensive investigation
into mechanisms that might be targeted to reproduce scar-free car-
diac regeneration in the adult heart (Cardoso et al., 2020). In fact, in
most models, scars are formed but are resolved as cardiomyocytes
proliferate alongside rebuilding of the vascular and lymphatic network
to replace the damaged heart tissue. The challenges of translating to
the adult heart are multiple, not least the need to reinstate significant
cardiomyocyte proliferation and the higher intracardiac pressures in
adult that necessitate rapid replacement of necrotic myocardium to
retain cardiac integrity. Differences in the inflammatory cell popula-
tion in adult compared with the neonatal heart (Lavine et al., 2014)
tend to promote scar formation, rather than resolution. Understanding
this scar resolution process may offer the best prospect of translation
from the neonatal model (Talman & Ruskoaho, 2016), with therapeu-
tic use of appropriately programmed macrophages to support myocar-
dial regeneration initiated by other interventions (see Section 5).
Along similar lines, new understanding of the differences between
angiogenesis in neonates and in the adult heart (Castellan, Vitiello,
et al., 2020) could support development of new interventions to pre-
vent the loss of cardiomyocytes or to support their replacement after
injury.
3 | CARDIAC PHENOTYPING AFTER MI
Advanced imaging methods for assessing human cardiac structure and
function include cardiac MRI with delayed contrast enhancement,
PET-CT, PET-MRI and single-photon emission CT (SPECT). Similar
imaging techniques can be applied in preclinical animal models for
phenotyping, or for clinical imaging tracer development (MacAskill
et al., 2021; Spath et al., 2020), but are not routinely used due to the
equipment required and associated costs. The most common methods
for assessing cardiac function following MI in preclinical studies are
discussed below.
3.1 | Echocardiography
Echocardiography imaging is commonly used to assess cardiac struc-
ture and function in animal models before and after CVD including
MI (see Gray et al., 2013; Zacchigna et al., 2021). The non-invasive
nature of this technique allows real-time repeated measures from
the same animal before intervention and throughout disease pro-
gression (Gao et al., 2000). Measures of LV chamber size during
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diastole (LV internal diameter at end diastole [LVIDd]) and systole
(LV internal diameter at end systole [LVIDs]) allow quantification of
fractional shortening [%FS; (LVIDd  LVIDs)∕LVIDd  100] as a
measure of LV contractility and systolic function. The LV ejection
fraction is a volumetric measure of systolic function and is defined
as the fraction of chamber volume ejected in systole (stroke volume
[SV]) in relation to the volume of blood remaining in the ventricle at
the end of diastole (end-diastolic volume [EDV]) [% ejection fraction
= (SV∕EDV)  100]. Following MI, LVIDd and LVIDs increase and %
FS and % ejection fraction decline (Gao et al., 2000; Sam
et al., 2000) as the LV undergoes systolic dysfunction. Two-
dimensional (2D) motion mode (M-mode) is most representative in
‘normally’ shaped ventricles and is typically used for assessing
hypertrophic remodelling by measuring the dimensions of the LV
including chamber size and wall thickness (septal and free wall). As
scar formation and remodelling of the LV after MI is non-
symmetrical and alters the geometry of the LV, volume and three-
dimensional (3D) measurements can give a more reliable estimate of
cardiac function. However, ejection fraction can be measured using
M-mode and the modified biplane Simpson's rule to correct for
shape distortions (Lang et al., 2006), The ejection fraction is most
accurately determined using special 3D imaging probes to avoid
geometric assumptions. More recently, global longitudinal strain
(GLS) by speckle tracking has been shown to yield a better assess-
ment of LV function, as it detects early LV dysfunction before
changes in ejection fraction occur and therefore is useful in diagnos-
ing HF with preserved ejection fraction (HFpEF) (An et al., 2016;
Karlsen et al., 2019).
Diastolic function is often assessed using pulsed Doppler imaging
whereby LV filling waves through the mitral valve are measured from
the apical four-chamber view that allows measures during early
(E wave) and late (atrial, A wave) diastole. The E/A ratio (1 physio-
logical value) can provide a measure of diastolic function (Park &
Marwick, 2011). Following MI, ventricular stiffness prolongs the time
constant of LV relaxation (τ), which leads to a smaller E wave and an
E/A ratio <1 (Nijland et al., 1997). However, separation of E and A
waves is often very challenging in the mouse because of its high
heart rate. Other measures include isovolumic relaxation time (IVRT;
interval from aortic valve closure to mitral value opening), ejection
time (ET) and isovolumic contraction time (IVCT; interval when all
heart valves closed). A prolonged ET or IVCT indicates systolic dys-
function, and prolonged IVRT indicates impaired diastolic function;
however, these short intervals can also be challenging to measure
accurately in mouse (Lindsey, Kassiri, et al., 2018). Assessment of
reverse longitudinal strain rate by speckle tracking provides more
sensitive detection of diastolic dysfunction and can be accompanied
by an increase in left atrial area (Schnelle et al., 2018). Limitations of
echocardiography include variability between users and laboratories,
particularly in mice due to technical challenges associated with small
heart size and high heart rates. Echocardiography is commonly used
alongside direct measures of cardiac function such as pressure–
volume loops (PVLs).
3.2 | Pressure–volume loops
Cardiac PVLs permit real-time measurement of LV pressure and vol-
ume concurrently, thereby providing global assessment of cardiac
physiology in vivo under load-dependent and load-independent condi-
tions (Townsend, 2016). PVLs provide invaluable and comprehensive
assessment of diastolic physiology, and by altering preload (through
transient occlusion of the inferior vena cava), load-independent mea-
sures of myocardial contractility can be obtained in rodents (Pacher
et al., 2008; Shioura et al., 2007). More recently, complete assessment
of cardiac function using biventricular PV loops has been achieved in
mice (Potus et al., 2020) and has the potential to be used clinically
(Bastos et al., 2020). Another advantage is the infusion of candidate
drugs alongside PVLs to investigate acute changes on cardiac function
(Kishi et al., 2001; Lee et al., 2017). The limitations of PVLs are the
challenging procedure requiring specialist skill to ensure correct posi-
tioning of a PV catheter (1.2 F for mouse) into the LV chamber (either
through the apex or retrogradely through the right carotid artery) and
importantly is generally terminal and so prohibits serial assessment of
disease or treatments, over time
The four phases of the cardiac cycle (isovolumetric contraction,
ejection, isovolumetric relaxation and passive filling) are shown by the
PV relationship as rectangular or trapezoidal loops generated by pre-
senting pressure on the Y axis and volume along the X axis. Following
MI, systolic dysfunction is observed by a decrease in dP/dtmax
(LV maximum derivative of change in pressure rise over time). Dia-
stolic dysfunction is shown by an increase in end-diastolic pressure
(EDP) and the isovolumic relaxation constant (τ) and a decrease in
dP/dtmin (LV minimum derivative of change in pressure fall over time)
(Lindsey, Kassiri, et al., 2018). Adverse post-MI remodelling can lead
to LV dilation, as seen by increased volume (ESV and EDV), increased
end-systolic pressure (ESP) and decreased EDP (Shioura et al., 2007).
The ESP–ESV relationship (ESPVR), a load-independent measure of
elastance or contractility, progressively declines after MI (Bastos
et al., 2020; Shioura et al., 2007). The EDP–EDV relationship (EDPVR)
represents passive filling of the LV and is a measure of compliance
(the inverse of stiffness). Due to increased myocardial stiffness as a
result of myocyte apoptosis and scar formation, LV compliance
decreases and EDPVR increases (Bastos et al., 2020).
3.3 | Biomarkers
Cardiac troponin I (cTnI) and T (cTnT) and N-terminal pro-B-type
natriuretic peptide (NT-proBNP) are the most common biomarkers
used to confirm experimental MI (Sicklinger et al., 2020; Sun
et al., 2018). cTnI and cTnT are regulatory proteins that control the
Ca2+-mediated contraction of cardiomyocytes, with predominant
expression in the myocardium (Park et al., 2017). Clinically, elevated
serum levels are the gold standard for diagnosis of myocardial ischae-
mia and necrosis, with levels correlating with adverse prognosis (Park
et al., 2017). NT-proBNP functions to inhibit the RAAS and serum
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levels correlate with infarct severity, predicting LV function and sur-
vival (Niu et al., 2014; Richards et al., 2003). Plasma BNP levels are
strongly increased during the early acute phase of MI (Morita
et al., 1993), and the expression of Nppb (the gene encoding NT-
proBNP) has been shown to be selectively up-regulated within the BZ
region and, in mice, is essential to prevent acute and lethal HF after
MI. Thus, measurement of these biomarkers permits assessment of
infarct size, which is the Number 1 predictor of adverse cardiac
remodelling and adverse cardiac events.
4 | EX VIVO AND IN VITRO RODENT
MODELS
Despite the fact that in vitro and ex vivo models of MI cannot capture
the complexity of the in vivo heart, they do offer valuable comple-
mentary information, when combined with in vivo models. Ex vivo
and in vitro models are valuable simplified methods to interrogate
molecular signalling pathways and electrophysiological alterations and
determine the efficacy of novel pharmacological agents, all in the
absence of confounding circulating influences such as neurotransmit-
ters, hormones and inflammatory factors (chemokines and cytokines),
in addition to the influence of other myocardial and circulating/
resident inflammatory cells (Gil Hernández et al., 2007; Kumar
et al., 2016). The ability to limit confounding factors in vitro and
ex vivo means that these models have greater predictability of patho-
physiology, compared with in vivo models. This greater control over
experimental conditions facilitates more rigorous testing of disease
processes and molecular pathways involved in MI.
4.1 | Isolated perfused hearts from rodents
The most well-known ex vivo method to induce MI is the Langendorff
perfused heart with LAD ligation, with or without reperfusion. The
Langendorff perfusion experiment involves heart isolation and perfu-
sion with an oxygenated buffer that contains nutrients in order for
the heart to sustain contractile function. The technique is well
established and easily modified to suit a wide range of animal species
such as mice (Conci et al., 2006), rats (Humphrey et al., 1980), guinea
pigs (Flores et al., 1984), ferrets (Flores et al., 1984), rabbits (Flores
et al., 1984), cats (Sack et al., 1976) and dogs (Nishikawa &
Tsujimoto, 1976). Crystalloid or blood perfusate in the Langendorff
system is delivered to coronary arteries via retrograde perfusion of
the cannulated aorta. The heart can be perfused either by constant
pressure, achieved by positioning a reservoir at a predetermined
height above the perfused heart, or by constant flow, by using a pump
to maintain a set flow rate (Bell et al., 2011). When the perfusate
reaches the cannulated aorta in a retrograde manner, it flows to the
coronary arteries via the coronary sinus at the root of aorta and drains
through the right ventricle and the pulmonary artery (Dhein, 2005).
Various parameters can be measured including infarct size, coronary
flow, ECG and myocardial contractility (from measures of ventricular
systolic and diastolic function). Ventricular pressure is normally mea-
sured with a pressure transducer attached to a fluid-filled balloon
inserted into the LV. In isolated hearts, ischaemia can be induced glob-
ally or regionally. In global ischaemia, flow of perfusate through all
arteries is completely stopped, whereas in regional ischaemia, only
one coronary artery is obstructed via ligation. Global ischaemia is eas-
ier to induce than regional ischaemia and often performed using a
constant pressure method. In contrast, applying regional ischaemia in
constant flow leads to an increase of perfusate pressure in the coro-
nary arteries, which can subsequently lead to damage (Bell
et al., 2011). Infarct size is usually measured at the end of reperfusion
by triphenyltetrazolium chloride (TTC) staining. TTC penetrates cells
and stains viable tissue, which contains NADPH a red colour, whereas
non-viable tissue remains unstained and appears pale in colour
(Mattson et al., 1947). TTC staining can be carried out using two
approaches. The first is single staining with TTC to determine viable
tissue during global ischaemia protocols (Ferrera et al., 2009). The
alternative method is a double-dye staining technique for regional
ischaemia protocols (Schwarz et al., 2000; Sumeray & Yellon, 1998). In
this method, the coronary artery ligation is retied at the end of the
reperfusion, and Evan's blue dye is infused into the aorta through
the cannula to stain the non-ischaemic area of the ventricular wall via
the coronary system (Schwarz et al., 2000; Sumeray & Yellon, 1998).
Following staining, the heart is sliced and further stained with TTC,
resulting in the infarcted myocardium remaining a pale colour,
whereas the area at risk (BZ) stains red and non-ischaemic areas stain
blue (RZ) (Schwarz et al., 2000; Sumeray & Yellon, 1998).
The Langendorff perfused isolated heart model has several
advantages such as the flexibility in controlling the protocol environ-
ments, enabling assessment of the direct effects of interventions
(e.g., pharmacological agents) on the heart, independently of the vas-
culature and circulating humoral factors. In addition, many studies use
the Langendorff model to assess mechanisms underlying arrhythmias
and cell death.
4.2 | Isolated cardiac cells from rodents
Cellular in vitro models can be used to study the morphological, physi-
ological and pathophysiological changes induced by hypoxia/
reoxygenation (H/R) injury in addition to cell response to genetic
modification or novel pharmacological interventions (Date
et al., 2002; Kang et al., 2000; Portal et al., 2013). A major advantage
of using in vitro models is the ability to expose cells to prolonged
periods of intervention that cannot be easily achieved in isolated
heart preparations (Gil Hernández et al., 2007; Kumar et al., 2016).
Additionally, this model can reduce the number of animals used in
experiments, has high reproducibility, can be designed to have multi-
ple layers of complexity (+/ genetic modification, prior in vivo PL or
I/R injury, and pharmacological intervention) and can be performed in
a high-throughput fashion.
Freshly isolated adult cardiomyocytes are the most physiologically
relevant cell type for studies mimicking MI insult; however, other
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studies have employed neonatal cardiomyocytes, embryonic cells,
human-induced pluripotent stem cell-derived cardiomyocytes (hIP-
SCs), progenitor cells and cell lines (H9c2 and HL-1). Adult
cardiomyocytes are preferable to neonatal cells as the latter are resis-
tant to hypoxia, and from a translational point of view, ischaemia
occurs predominantly in adult patients (Bishop, 2021; Riehle &
Bauersachs, 2019; Tanaka et al., 1994). One obstacle when using
adult cells to study contractile function during H/R is that
cardiomyocytes rapidly become energy-depleted during contraction,
following which cells have an increased propensity to die or to have
decreased function after recovery (Hausenloy & Yellon, 2010).
Hypoxic environments can be created using (<1% O2, 5% CO2
and 94%+ N2) with absolute substrate depletion (glucose-free and
serum-free medium) (Hausenloy & Yellon, 2010). This hypoxic envi-
ronment can be modified to more closely simulate ischaemic cardiac
insult by altering substrate levels in culture media, subjecting cells to
acidic conditions and electrolyte imbalances such as K+ and Ca2+
overload, and these changes can be coupled with electrical stimulation
of cardiomyocytes, to better simulate in vivo ischaemic conditions
(Kumar et al., 2016). These in vitro models allow assessment of cellu-
lar death processes such as apoptosis and necrosis, mitochondrial dys-
function, changes to electrophysiology and Ca2+ handling, action
potential duration (APD) and specific biochemical/signalling pathways
(Maciel et al., 2021).
5 | TRANSLATION: USE OF MI MODELS IN
CARDIOVASCULAR RESEARCH
In general, the use of animal models of MI is highly valued in three
broad areas of cardiovascular research: (i) mechanistic studies (involv-
ing, e.g., infarct repair, adverse cardiac remodelling, cell death and
arrhythmias); (ii) translational studies (e.g., assessing pharmacological/
interventions in the disease setting to improve outcome); and
(iii) studies with advanced therapies to improve cardiac function, tis-
sue remodelling and regeneration (e.g., gene and cell therapy and
tissue engineering).
5.1 | Mechanistic studies
The key hallmarks of adverse cardiac remodelling in patients are pre-
sent in animal models of MI (Lindsey, Bolli, et al., 2018). Indeed, animal
models are particularly well suited to studying the temporal and spa-
tial changes in adverse cardiac remodelling. This includes processes
and mechanisms that occur early following MI such as cell death,
reperfusion injury, inflammatory/immune responses, fetal gene reac-
tivation and those that may occur over a longer timescale for example
fibrosis, development of arrhythmias, changes to ventricular wall/
chamber geometry and architecture.
Traditionally, much research has focused on examining processes
and mechanisms contributing to adverse cardiac remodelling at one to
several weeks following MI. However, it is important to recognise that
many of the processes that change in the first few hours and days fol-
lowing MI dictate the later outcomes (French & Kramer, 2007;
Heidary et al., 2010; Jackson et al., 2002; White et al., 2016). Further-
more, the importance of early changes in particular regions of the
heart following MI has become increasingly recognised (Gilson
et al., 2007; Zhang et al., 2012). In particular, events that occur in the
BZ region in the first few days after MI play a critical role in the pro-
gression of LV remodelling during the following weeks and months.
For example, early temporal and spatial parameters play a key role in
cardiac contraction following MI. Rodent studies confirm that global
LV contractile function is substantially reduced as early as 1 day after
MI (Palojoki et al., 2001; Song et al., 2012). At this time point and
across species, regional heterogeneity of contractile function across
the LV (with severe dysfunction in the IZ [Epstein et al., 2002; Kramer
et al., 1993; Kramer et al., 1996]) contributes to impaired global LV
contractile function. The juxtaposition of cardiomyocytes in the BZ
between largely contractile (RZ) and non-contractile (IZ) regions
(French & Kramer, 2007) results in non-uniform wall stress patterns in
the BZ. This wall stress stimulates induction of hypertrophic factors,
LV dilation, arrhythmogenesis (Quinn & Kohl, 2021) and poor patient
prognosis (French & Kramer, 2007; Heidary et al., 2010; Jackson
et al., 2002). Indeed, improving contractility specifically within the BZ
region at 1 day after MI improved global LV contractile function, inde-
pendent of infarct size (Gilson et al., 2007; Zhang et al., 2012). Differ-
ences in BZ and RZ cardiomyocyte SR-mediated Ca2+ release and
contractility acutely after MI contribute to this regional heterogeneity
of contractile function. The BZ region has reduced expression of the
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), amplitude of Ca2
+ transients and contraction (Licata et al., 1997; Yoshiyama
et al., 1997). In contrast, cardiomyocytes from the RZ demonstrate an
initial compensatory phase of increased/maintained Ca2+ transient
amplitude, an increased diastolic Ca2+ (a trigger for activation of
hypertrophic signalling), an increased SERCA/phospholamban (PLB)
ratio and greater cell contractility (for up to 1 week after MI) inde-
pendent of action potential changes (Mørk et al., 2009; Sandmann
et al., 1999; Yoshiyama et al., 1997; Yue et al., 1998). Eventually, this
compensatory phase in the RZ is followed by the well-known later
failing phase (depressed cell contractility and peak Ca2+ transient
amplitude with slower decline).
Another example of temporal and regional changes that dictate
outcome after MI is reactivation of fetal genes and transcription fac-
tors. Genes that can change include the induction of the classical
markers, atrial natriuretic peptide (ANP) and BNP (Calderone
et al., 2006; Cameron et al., 2000; van Duijvenboden et al., 2019) as
well as more recent discoveries including the observation that Runx1
expression is increased in BZ cardiomyocytes in the first 24 h follow-
ing MI and drives adverse cardiac remodelling, including cardiac dila-
tion, eccentric hypertrophy and impaired cardiac contraction
(McCarroll et al., 2018; Riddell et al., 2020).
A key area of research where models of MI are used to great
effect is studying how the infarct and remodelled myocardium can
lead to the generation of arrhythmias. Much has been learnt using ani-
mal models of MI regarding novel interactions between denervated
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myocardium within the infarct and BZ in sustaining life-threatening
arrhythmias. Following I/R, sympathetic re-innervation of the infarct
is prevented by the production of chondroitin sulphate proteoglycans
(Gardner et al., 2016; Gardner & Habecker, 2013). Trans-
differentiation of sympathetic neurons can occur after I/R, causing
sympathetic cholinergic transmission (Wang et al., 2020). Conversely,
following PL, chondroitin sulphate proteoglycans are not produced,
and instead, hyperinnervation of the infarct occurs, resulting in het-
erogeneous innervation between the IZ, BZ and RZ (Gardner
et al., 2016). The heterogeneity of innervation after PL causes
increased dispersion of repolarisation and thus increased risk of
arrhythmia (Ajijola et al., 2017; Zhou et al., 2004).
With mechanistic studies, it is often desirable to use the PL
method in the first instance particularly where the size of the effect is
unknown. The PL results in more severe injury, easily detectable
changes in adverse cardiac remodelling and in general a larger reduc-
tion of ventricular contraction compared with I/R models (de Villiers &
Riley, 2020).
5.2 | Translational and regenerative studies
Animal models of MI are a powerful experimental tool to assess and
develop novel treatment strategies and provide information regarding
drug efficacy, mechanism of action (MOA) and safety often rep-
resenting the first key steps on the translational pathway. Several ani-
mal model studies have proved critical in developing many of our
most clinically relevant cardiac drugs.
As has been mentioned, an early example of this was the studies
using animal models of MI, which underpinned the use of ACE inhibi-
tors as standard treatment for patients with MI (Pfeffer et al., 1992;
Pfeffer, Pfeffer, & Braunwald, 1985; Pfeffer, Pfeffer, Steinberg, &
Finn, 1985). ACE inhibitors block the conversion of angiotensin I to
angiotensin II, thereby counteracting the effects of the RAAS, by
decreasing BP and adverse cardiac remodelling (Alonso Salinas &
Zamorano Gomez, 2017). The preclinical studies, which used a coro-
nary artery ligation rat model of MI and cardiac failure, were critical in
establishing that ACE inhibitors could reduce systemic vascular resis-
tance, left filling pressures and subsequent LV dilation through their
inhibitory effects on the RAAS (Pfeffer et al., 1992; Pfeffer, Pfeffer, &
Braunwald, 1985; Pfeffer, Pfeffer, Steinberg, & Finn, 1985). These
studies also suggested that these effects were sustained with chronic
administration of ACE inhibitors and that early and chronic adminis-
tration of these inhibitors could reduce mortality in rats with chronic
MI and HF (Pfeffer et al., 1992; Pfeffer, Pfeffer, & Braunwald, 1985;
Pfeffer, Pfeffer, Steinberg, & Finn, 1985). Importantly, these initial
findings on the efficacy of chronic use of ACE inhibitors in rats were
later validated in humans (Pfeffer et al., 1992; Pfeffer, Pfeffer, &
Braunwald, 1985; Pfeffer, Pfeffer, Steinberg, & Finn, 1985).
ARBs are a class of drugs that decrease angiotensin II-induced
increases in BP, aldosterone activation and adverse cardiac
remodelling by blocking angiotensin AT1 receptors (Burnier, 2001).
Preclinical models have proved useful in establishing novel aspects
regarding the MOA of ARBs. For example, the ARB valsartan signifi-
cantly decreased LV remodelling and improved systolic function in a
mouse model of MI using coronary artery ligation (Higashikuni
et al., 2012). The use of valsartan was associated with reduced cardiac
hypertrophy, fibrosis, oxidative stress and pro-inflammatory cytokine
expression (Higashikuni et al., 2012). These effects were also
observed in human clinical trials where valsartan was shown to signifi-
cantly reduce post-MI LV remodelling and improve overall cardiac
function (Park et al., 2018).
ARNIs are a newer class of cardiac drugs that contain a combina-
tion of an ARB and an inhibitor of the enzyme neprilysin (Hubers &
Brown, 2016). In this setting, the effects of the ARB are combined
with inhibition of the enzyme neprilysin, which normally breaks down
natriuretic peptides (Hubers & Brown, 2016). This increases natri-
uretic peptide activity and their associated vasodilatory effects in the
heart (Hubers & Brown, 2016). In such, ARNI therapy ameliorates
the imbalances between natriuretic peptide and RAAS in cardiac dis-
ease (Hubers & Brown, 2016). Preclinical models have provided
important insight into the MOA of ARNI and highlighted important
differences between ARNI and ARB therapy in the context of MI. For
example, an important study by Pfau et al. (2019) compared the
effects of ARNI (sacubitril/valsartan) and ARB (valsartan) only, on
adverse cardiac remodelling and cardiac function in a coronary artery
ligation rat model of MI and HF. Importantly, although both ARNI and
ARB were shown to improve LV function and cardiac remodelling,
these effects were more consistent following ARNI therapy (Pfau
et al., 2019). Furthermore, ARNI therapy had additional beneficial
effects such as reducing cardiomyocyte hypertrophy, decreasing inter-
stitial fibrosis, increasing VEGFA expression and increasing angiogen-
esis and overall perfusion of the infarct (Pfau et al., 2019). Therefore,
this rat study provided critical insight into the mechanisms by which
ARNI could improve cardiac function in MI and highlighted key mech-
anistic differences between ARNI and ARBs, further supporting their
use in humans with MI. Indeed, ARNI therapy significantly decreased
hospitalisation and improved outcomes in patients suffering from HF
with reduced ejection fraction (HFrEF) (Hubers & Brown, 2016;
McMurray et al., 2014).
More recent developments with translational potential include
medicines classed as advanced therapies, including gene and cell ther-
apies and tissue engineering. A range of different interventions within
animal models of MI have been investigated to further our under-
standing of the therapeutic potential of these therapies. In gene ther-
apy, a large number of preclinical studies have been successfully
undertaken to assess therapeutic targets delivered via non-viral, ade-
noviral, lentiviral or adeno-associated virus (AAV) vectors to investi-
gate prevention of adverse cardiac remodelling, improve cardiac
function and stimulate angiogenesis after MI (Antonio et al., 2020).
AAV vectors, in particular those based on serotypes 1, 6 and 9, have
attracted great interest based on their intrinsic tropism for the heart
and ability to deliver a wide range of candidate therapeutic genes.
These include components of the RAAS (Fattah et al., 2016), calcium-
handling proteins (Fish et al., 2013), extracellular mediators (Pleger
et al., 2011) and proangiogenic growth factors (Tao et al., 2011). A
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more recent development has been the identification of the therapeu-
tic potential of non-coding RNA. The use of rodent models of MI has
also demonstrated the benefits of delivering non-coding RNA via viral
vector-mediated gene therapy for heart disease and cardiac regenera-
tion. For example, human microRNAs miR-590 and miR-199a induce
cardiomyocyte proliferation and stimulate cardiac regeneration in a
mouse MI model when delivered via AAV9 (Eulalio et al., 2012). The
same group demonstrated the importance of assessing this therapy in
different preclinical models and at different time points, which exem-
plifies the importance of preclinical models in determining the efficacy
and MOA of therapeutic agents (Gabisonia et al., 2019). Human
miR199a delivery, via AAV6 in a pig model of MI, stimulated cardiac
repair and improved contractility at 1 month after MI. However,
follow-up for 2 months revealed that a number of animals died
through proarrhythmic events believed to be driven through uncon-
trolled microRNA expression leading to infiltration of poorly differen-
tiated proliferating cells into the myocardium (Gabisonia et al., 2019).
This highlights the importance of preclinical models in predicting
safety profiles of novel cardiovascular therapeutic agents, before
human clinical trials.
One of the main aims of cardiac regeneration is to use gene trans-
fer to stimulate cardiomyocyte proliferation to replace the 1 billion
cardiomyocytes that die in the first few hours following MI (Antonio
et al., 2020). An alternative approach to directly induce cardiomyocyte
proliferation to replace loss of cardiac muscle, is to utilise grafts that
can be composed of various biomechanical components. Animal
models of MI are excellent in determining the efficiency and viability
of such grafts. For example, human engineered heart tissue
strips transplanted onto infarcts following MI integrate with the sur-
viving myocardium and show cardiomyocyte proliferation and
vascularisation, ultimately contributing to improved whole heart con-
tractility following MI (Weinberger et al., 2016). Studies to assess cell
therapies using a range of different cell sources, including
haematopoietic and mesenchymal stem cells, cardiac progenitor cells
and pluripotent stem cells, have demonstrated benefits on cardiac
remodelling and function in models of MI. For example, mesenchymal
stem cells, delivered via a hydrogel to improve cardiac retention, pro-
vided long-term cardiac protection after MI in mice (Chen
et al., 2020). Furthermore, bone marrow stem cells transduced with
lentiviral vectors to overexpress insulin-like growth factor-1 (IGF-1)
demonstrated greater protective effects than control stem cells in a
rat model of MI (Lin et al., 2020). More recently, research has demon-
strated that protective effects of stem cells may in part be due to
release of extracellular vesicles and subsequent paracrine signalling in
models of MI, raising the possibility of novel cell-free therapies in the
future (Santoso et al., 2020).
With translational studies, it is often the case that the I/R model
is used because this model most resembles clinical treatment for
patients with MI, for example, PPCI. Furthermore, reperfusion repre-
sents a window of opportunity to apply therapeutic interventions.
However, it is important to note that translational studies are also
applicable to the PL model because there are a substantial number of
patients (30%) admitted to hospital too late to acquire the benefits
afforded by reperfusion therapy (Cohen et al., 2010). Given that the
infarct size and adverse cardiac remodelling associated with the I/R
model can be more variable and smaller than with the PL model, it is
often beneficial to first assess the translational benefits in the latter
model before proceeding to the I/R model. As with all animal experi-
ments, there is a need to ensure alignment of the study design with
the ARRIVE guidelines to ensure that the translational benefits
observed are reproducible and robust. Once results are confirmed in
rodent models, the next stage on the translational pathway is often
the replication of the study in a large animal model, such as the pig,
before progression to human clinical trials. This has been demon-
strated for a novel miR-132 antisense drug (CDRL132L), where find-
ings from a porcine I/R model were translated in a Phase Ib study,
showing improvements in cardiac function (Batkai et al., 2021; Täubel
et al., 2021). In this study, important information regarding pharmaco-
kinetics, MOA and safety was provided by the porcine I/R model,
prior to human studies, which further highlights the importance of
preclinical models in the drug development process.
It is important to note that although models of MI are critical
and indeed essential in determining the translational benefits of
interventions to prevent many of the adverse mechanisms that lead
to HF, the model of MI itself does not always lead to HF in the spe-
cies of choice. This is particularly the case in the mouse that
undergoes considerable adverse cardiac remodelling but can sustain
compensated LV cardiac dysfunction for substantial periods of time
without signs of decompensation and development of HF, for exam-
ple, increased lung weight (pulmonary oedema) together with exer-
cise intolerance. Key variables at play here include size of infarct,
genetic strain, duration of study after MI and existence of co-morbid-
ities. Therefore, from a translational point of view, it is important to
carefully interpret data regarding the efficacy, safety and MOA of
novel therapeutic agents, relative to important species differences in
disease pathogenesis.
6 | CHALLENGES OF TRANSLATION
The primary challenge of translation is in selecting the most appropri-
ate model. A truly translational model would be multifaceted to repro-
duce the clinical situation and would require I/R, as discussed above,
and take into account the older age of typical patients, as well as sex,
co-morbidities (e.g., diabetes, hypertension and obesity) and concur-
rent therapies (extensively reviewed elsewhere [Davidson et al., 2019;
Ferdinandy et al., 2014; Hausenloy et al., 2013; Hausenloy
et al., 2016, 2017; Lecour et al., 2014; Zwetsloot et al., 2017]). All of
these factors can individually influence outcomes, especially infarct
size in MI models, and create variability that alters the therapeutic
window in which effectiveness of new interventions can be tested. It
is usually necessary to find a compromise that balances the need for a
reproducible and cost-effective experimental model, with relevance
for translation to humans.
The choice of model might be dictated by the development stage
of the new intervention or by the pathway under investigation. High-
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throughput screening for a specific target is more straightforward in
isolated cardiomyocytes or in fish and rodents than in large animals,
but large animals are likely to be more predictive of outcome in the
clinic. Cardioprotective signalling in pigs is thought to be closer to that
in humans, compared with rodent hearts, making it a likely more pre-
dictive model of translation for agents designed to protect
cardiomyocytes from death following ischaemia (Heusch et al., 2011).
However, as discussed previously, key differences in cardiomyocyte
growth in pigs (Velayutham et al., 2020) might make them a less
appropriate model if this is the target under investigation for thera-
peutic intervention.
As in all drug development studies, it is important to consider that
the drug pharmacokinetics might be quite different when moving
between species during the development process. Early testing is
essential to design a dosing regimen that ensures achievement of an
effective dose. In the case of MI, specific drug interventions are already
established for use during PPCI and to limit later remodelling. Any new
intervention would have to be effective in the setting where these
drugs are already in place, and good design would take these concur-
rent therapies into account, but this can change pharmacokinetics and
drug effectiveness in the model. The drug target itself can be species
specific, for example, an enzyme active site. Multiple drug candidates
optimised for rodent, pig and human might therefore be required.
Biological sex has an important impact on gene transcription
(Oliva et al., 2020), and in the heart, it is well established that infarct
size is reduced across species in females, compared with males.
Funding bodies, including the NIH (Clayton & Collins, 2014), and,
increasingly, academic journals recommend that studies take out-
comes in males and females into account at the design stage. This rep-
resents good practice, especially for translation, but adds cost and in
terms of identifying drug action in MI models and reduces the thera-
peutic window to identify benefit in females.
7 | CONCLUDING REMARKS
Preclinical models are important experimental tools that have sig-
nificantly enhanced our understanding of the pathogenesis of MI
and the benefit of therapeutic interventions used to treat
MI. Importantly, however, no single preclinical model can perfectly
reproduce the complexity of MI in humans. For example, there are
some differences in the pathogenesis of MI and HF between
humans and other species. Furthermore, it can be challenging to
recreate the complexity of MI using in vitro and ex vivo models.
Therefore, it is imperative for scientists to carefully select the
appropriate preclinical model based on the scientific question being
asked. Furthermore, an understanding of the limitations of the pre-
clinical model in question is essential to maximise the translational
potential of laboratory findings. Despite the drawbacks of preclini-
cal models of MI, their importance for uncovering novel therapeu-
tic targets and for studying the efficacy of innovative
pharmaceuticals and advanced treatment strategies remains highly
relevant and significant.
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmacology.org and
are permanently archived in the Concise Guide to PHARMACOLOGY
2019/20 (Alexander, Christopoulos et al., 2019; Alexander, Fabbro
et al., 2019a,b; Alexander, Kelly et al., 2019).
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